Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
148 Clinical Paid Trials near Knoxville, TN
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerVeraCept IUD for Preventing Pregnancy
Chattanooga, Tennessee
To assess the contraceptive efficacy (prevention of pregnancy) of VeraCept
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:< 45
Sex:Female
Key Eligibility Criteria
Disqualifiers:Pregnancy, Cancer, HIV, Others
Must Not Be Taking:Hormonal Contraceptives
1620 Participants Needed
Varenicline + Counseling for Smoking Addiction
Pickens, South Carolina
The purpose of this study is to better understand tobacco outcomes using a commonly prescribed stop smoking medication (varenicline) and financial incentives for adults who also use cannabis. Varenicline is not FDA approved for e-cigarette cessation, but is FDA approved for cigarette cessation. Investigators are also interested in how cannabis/marijuana and tobacco interact during a tobacco quit attempt. All participants will receive e-cigarette cessation treatment for 12 weeks. To qualify, participants must be between the ages of 18-40 and use both e-cigarettes and cannabis. Participants do not need to be interested in quitting cannabis to qualify. This study is being conducted at three sites: the Medical University of South Carolina in Charleston, SC, Behavioral Health Services in Pickens, SC, and MUSC Lancaster in Lancaster, SC.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 40
Key Eligibility Criteria
Disqualifiers:Serious Psychiatric Disorders, Cigarettes, Others
Must Be Taking:Varenicline
105 Participants Needed
GEN-1 + NACT for Ovarian Cancer
Chattanooga, Tennessee
This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus NACT compared to NACT alone.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Sex:Female
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, Other Malignancies, Hepatitis, CNS Disease, Others
Must Not Be Taking:Corticosteroids, Immunosuppressants
130 Participants Needed
BCG + N-803 for Bladder Cancer
Chattanooga, Tennessee
This is a Phase Ib/IIb, randomized, two-cohort, open-label, multicenter study of intravesical N-803 plus BCG versus BCG alone, in BCG naïve patients with high-grade NMIBC.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Muscle-invasive Cancer, HIV, CHF, Others
Must Be Taking:BCG Therapy
596 Participants Needed
BGB-16673 for B-Cell Cancers
Chattanooga, Tennessee
This trial tests a new drug called BGB-16673 to find the best dose for patients. It aims to determine how well the drug works and its safety. The study involves finding the right dose and expanding testing to more patients.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Prior Malignancy, CNS Involvement, Others
Must Be Taking:BTK Inhibitors
614 Participants Needed
ART0380 for Advanced Cancer
Chattanooga, Tennessee
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to:
* Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan
* Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan
* Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, HIV/AIDS, Hepatitis, Others
Must Not Be Taking:UGT1A1 Inhibitors
502 Participants Needed
Mosunetuzumab + Lenalidomide for Follicular Lymphoma
Chattanooga, Tennessee
This study will evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of mosunetuzumab (Mosun) + lenalidomide (Len) (Mosun + Len) in participants with follicular lymphoma (FL). This study will also compare the pharmacokinetics, pharmacodynamics, safety, efficacy, and immunogenicity of IV mosunetuzumab + len vs subcutaneous (SC) mosunetuzumab + len.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:CNS Lymphoma, Hepatitis B, Others
Must Not Be Taking:Immunosuppressants, Thalidomide
237 Participants Needed
ONC-392 + Pembrolizumab for Non-Small Cell Lung Cancer
Chattanooga, Tennessee
This trial tests ONC-392, an antibody that helps the immune system fight cancer, in patients with advanced or spreading tumors who haven't responded to other treatments. It works by blocking a protein that usually keeps immune responses in check, making it easier for the body to attack cancer cells.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Active Brain Metastasis, Active Infection, Others
Must Not Be Taking:Chronic Steroids
733 Participants Needed
Novel Cancer Therapies for Colorectal Cancer
Chattanooga, Tennessee
COLUMBIA-1 is a Phase 1b/2 platform study to evaluate the safety and efficacy of standard of care (FOLFOX plus bevacizumab) alone and in combination with novel oncology therapies in first-line metastatic microsatellite-stable colorectal cancer (MSS-CRC).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Not Listed
61 Participants Needed
Niraparib + Standard Therapy for Prostate Cancer
Seneca, South Carolina
This is a phase I-II trial to find the safety and activity of adding a new drug (neraparib) to the usual treatment (radiation combined with male hormone deprivation therapy) in lowering the chance of prostate cancer growing or returning. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Adding niraparib to the usual care may lower the chance of prostate cancer growing or returning.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Sex:Male
Key Eligibility Criteria
Disqualifiers:Metastatic Disease, Active Malignancy, Others
Must Not Be Taking:Anti-androgens, HAART, PARP Inhibitors
22 Participants Needed
Enfortumab Vedotin for Bladder Cancer
Chattanooga, Tennessee
This trial is testing a new drug called enfortumab vedotin alone and with other treatments in patients with advanced or muscle-invasive bladder cancer. The goal is to see how well these treatments work and what side effects they might have. Enfortumab vedotin targets and kills cancer cells, while pembrolizumab helps the immune system fight the cancer.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Uncontrolled Diabetes, Others
Must Be Taking:Pembrolizumab
348 Participants Needed
DR-01 for Alopecia Areata and Vitiligo
Chattanooga, Tennessee
This is a multi-center, parallel-group, open-label, randomized, Phase 1b study to explore the safety, clinical activity, pharmacokinetics and pharmacodynamics of DR-01 in adults with Alopecia Areata or Vitiligo.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Malignant Disease, Autoimmune Diseases, Others
Must Be Taking:Bimatoprost, Minoxidil
80 Participants Needed
DISC-0974 for Anemia in Chronic Kidney Disease
Dalton, Georgia
This trial tests a new drug called DISC-0974 in adults with chronic kidney disease who are not on dialysis and have anemia. It aims to see if the drug is safe and how it behaves in and affects the body.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Dialysis, Hemolytic Anemia, Hemochromatosis, Others
Must Not Be Taking:Oral Iron, ESAs, IV Iron
50 Participants Needed
RO7759065 + Atezolizumab for Cancer
Chattanooga, Tennessee
This is a first-in-human Phase Ia/Ib, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of RO7759065 as a single agent (Phase Ia) or in combination with atezolizumab (Phase Ib) in patients with locally advanced, recurrent, or metastatic incurable solid tumor malignancies. Several key aspects of the study design and study population are summarized below.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Pregnancy, HIV, Autoimmune Disease, Others
Must Not Be Taking:Chemotherapy, Hormonal Therapy
310 Participants Needed
BNT331 for Bacterial Vaginosis
Chattanooga, Tennessee
This is a two-part, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy (for Part B) of BNT331 in healthy women (Part A) and in women diagnosed with bacterial vaginosis (BV) (Part B).
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Sex:Female
Key Eligibility Criteria
Disqualifiers:Pregnancy, Genital Lesions, Drug Abuse, Others
Must Not Be Taking:Antifungals, Antimicrobials, Vaginal Hormones
102 Participants Needed
Intravesical Enfortumab Vedotin for Bladder Cancer
Chattanooga, Tennessee
This trial tests a new treatment for bladder cancer by delivering the drug directly into the bladder through a thin tube. The study will determine the best dose and evaluate its effectiveness and side effects.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Muscle-invasive Cancer, Metastatic Disease, Others
Must Not Be Taking:Chemotherapy, Immunotherapy, Others
58 Participants Needed
T-DXd Combinations for Breast Cancer
Chattanooga, Tennessee
This trial is testing T-DXd with other treatments in patients with a specific type of advanced breast cancer that has low levels of HER2. The study aims to find the best dose and see how well the treatment works and how safe it is. T-DXd is a new treatment that has shown promising outcomes in various studies for advanced breast cancers with different levels of HER2.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Cardiovascular Disease, ILD, CNS Metastases, Others
Must Not Be Taking:IV Antibiotics, Antivirals
138 Participants Needed
MEDI5752 for Solid Cancers
Chattanooga, Tennessee
This trial is testing a new drug called MEDI5752 along with common chemotherapy drugs in adults with advanced cancer. The goal is to see if MEDI5752 can help fight cancer on its own or when combined with chemotherapy.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Autoimmune Disorders, Organ Transplant, Others
Must Not Be Taking:Immunosuppressants, Live Vaccines
401 Participants Needed
E-Cigarettes or Medication for Tobacco Use
Pickens, South Carolina
The purpose of this study is to investigate whether non-cigarette tobacco products, namely e-cigarettes (nicotine vapes), can help people who smoke and are in treatment for substance use disorder quit smoking by switching completely to e-cigarettes as compared to FDA-approved medications, namely nicotine replacement therapy in the form of patches and lozenges. Participation will last 6 months and will include five in-person study visits and eleven virtual assessments. Participants will also complete a short daily diary on their phones each day for the first twelve weeks. To qualify, participants must be within 30 days of SUD treatment program admission. This study is being conducted at three outpatient SUD treatment programs across South Carolina. These sites include: 1) the Center for Drug and Alcohol Problems (CDAP) in Charleston, SC, 2) Behavioral Health Services of Pickens County (BHSPC) in Pickens, SC, and 3) Shoreline Behavioral Health Services in Conway, SC. the Medical University of South Carolina in Charleston, SC, Behavioral Health Services in Pickens, SC, and the Medical University of South Carolina in Florence, SC.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:21+
Key Eligibility Criteria
Disqualifiers:Unstable Medical, Psychiatric, Pregnancy, Others
Must Not Be Taking:Smoking Cessation Drugs
240 Participants Needed
Virtual Reality for Hospice Care
Seneca, South Carolina
Background: Nature-based virtual reality (VR) and other outdoor experiences in head-mounted displays (HMDs) offer powerful, non-pharmacological tools for hospice teams to help patients undergoing end-of-life (EOL) transitions. However, the psychological distress of the patient-caregiver dyad is interconnected and highlights the interdependence and responsiveness to distress as a unit. Hospice care services and healthcare need strategies to help patients and informal caregivers with EOL transitions.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Not Listed
11 Participants Needed
Why Other Patients Applied
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."
FF
ADHD PatientAge: 31
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
MAGENTIQ-COLO for Colonoscopy
Chattanooga, Tennessee
This is an international, multicenter, study to evaluate the diagnostic performance of the CADx polyp sizing modality of the MAGENTIQ-COLO.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:45 - 80
Key Eligibility Criteria
Disqualifiers:Inflammatory Bowel Disease, Polyposis, Pregnancy, Others
Must Not Be Taking:Anticoagulants
330 Participants Needed
Left Atrial Appendage Closure Device for Atrial Fibrillation
Chattanooga, Tennessee
An evaluation of the safety and performance of the Conformal Left Atrial Appendage Seal for Left Atrial Appendage Occlusion
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Pregnancy, Severe Heart Failure, Stroke, Others
Must Be Taking:Oral Anticoagulants
64 Participants Needed
FemBloc vs Laparoscopic Sterilization for Birth Control
Chattanooga, Tennessee
Prospective, multi-center, international, non-randomized, two-arm study of subjects undergoing either FemBloc or laparoscopic bilateral tubal sterilization (Control). The FemBloc group total study duration will be approximately 65 months. The laparoscopic tubal sterilization (Control) group total study duration will be approximately 62 months.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:21 - 45
Sex:Female
Key Eligibility Criteria
Disqualifiers:Pregnancy, Prior Tubal Surgery, Others
240 Participants Needed
Cardiac MRI for Breast Cancer
Seneca, South Carolina
This study is being done to see if patients receiving chemotherapy for breast cancer affects the heart, the ability to exercise and fatigue when compared to patients who do not have cancer.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Sex:Female
Key Eligibility Criteria
Disqualifiers:Heart Disease, Hypertension, Diabetes, Others
Must Be Taking:Chemotherapy, Estrogen Antagonists
403 Participants Needed
mRNA-1403 for Stomach Flu
Bristol, Tennessee
The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prevent protocol-defined moderate or severe norovirus acute gastroenteritis (AGE) associated with vaccine matched genotypes.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Chronic GI Disease, Immunodeficiency, Others
Must Not Be Taking:Immunosuppressants, Blood Products
28000 Participants Needed
Online Decision Aid for Prostate Cancer Screening
Clemson, South Carolina
The goal of this clinical trial is to learn if the online, simulated human "Talk to Nathan About Prostate Cancer Screening" decision aid (https://www.cdc.gov/prostate-cancer/talk-to-nathan/index.html) is effective in helping patients decide about prostate cancer screening. The main questions it aims to answer are:
* Is using the "Talk to Nathan About Prostate Cancer Screening" decision aid effective in improving knowledge, overcoming health literacy barriers, and resolving decisional conflict compared to a standard decision aid or standard education materials?
* What are the barriers and best practices for incorporating Talk to Nathan About Prostate Cancer Screening into the flow of primary care practice?
Researchers will compare "Talk to Nathan About Prostate Cancer Screening" to a standard decision aid and to standard prostate cancer screening education materials to test the effectiveness of using "Talk to Nathan About Prostate Cancer Screening."
Participants will:
* Use "Talk to Nathan About Prostate Cancer Screening," use a standard decision aid, or use standard education materials about prostate cancer screening
* Visit the primary care clinic for follow-up
* Complete surveys as part of the clinical trial
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:55 - 69
Sex:Male
Key Eligibility Criteria
Disqualifiers:Urinary Symptoms, Prostate Cancer, Terminal Illness, Others
510 Participants Needed
Online Platforms for Alzheimer's Disease Information Delivery
Bristol, Tennessee
This randomized non-inferiority study will evaluate self-directed scalable electronic health platform (eHealth) methods for communicating Alzheimer's gene and biomarker results compared to videoconference telehealth disclosure with healthcare providers, as well as characterize the impacts of learning this information on the participant.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:60 - 80
Key Eligibility Criteria
Disqualifiers:Psychiatric Illness, Communication Difficulties, Others
681 Participants Needed
Nature Exposure for Mental Health
Clemson, South Carolina
This project will first examine nature opportunities, belonging and benefits with a multi-state nature-based intervention with a focus on students of color. In light of the syndemic, 'nature deficit disorder' and poor mental health, the investigators anticipate several far-reaching impacts that will (a) test a nationally useful standardized way to quantify exposure; (b) invest in nature resources and accessibility on campuses; and (c) promote the mental health and therapeutic benefits of nature among young adults. These will lead to understanding the nature exposure and mental health interplay and techniques for quantifying and encouraging nature exposure to treat the on-going youth mental health crisis. Including HBCUs and an hispanic-serving institution is expected to result in heightened visibility of underlying disparities, including structural racism and land-based violence and discrimination, that have contributed to current-day nature gaps and dismantled nature relationships for students of color.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 24
Key Eligibility Criteria
Disqualifiers:Not Undergraduate, Age, Distance
1500 Participants Needed
Know someone looking for new options?
Spread the word